Lifecare (LIFE) Q1 2025 earnings summary

Executive summary

• Advancing toward market launch of next-generation implantable CGM for diabetes, with design optimization, manufacturability nearing completion, and improved sensor sensitivity enhancing accuracy and performance for both human and veterinary markets.

• Business model centers on in-house R&D and production, leveraging a scalable B2B approach, strategic partnerships, and a new production facility in Mainz, Germany opening in Q3 2025.

• Addressable market estimated at USD 5 billion, with ambitions for $200 million+ annual revenue by 2030 and peak revenue potential over $1 billion.

• Intellectual property protected by patents, with digital integration enhanced through collaboration with OneTwo Analytics AB.

Financial highlights

• Q1 2025 revenue was NOK 4,000, down from NOK 1,277,000 in Q4 2024 and NOK 411,000 in Q1 2024, reflecting limited external sales.

• Operating expenses for Q1 2025 totaled NOK 25 million, down from Q4 2024 but up year-over-year due to increased R&D and production readiness.

• Operating loss for the quarter was NOK 25 million, with net loss after tax at NOK 20.3 million.

• Net cash outflow of NOK 21.2 million; cash position at quarter-end was NOK 40.4 million.

• Equity ratio declined to 60% from 77% year-over-year, reflecting increased liabilities and investments.

Outlook and guidance

• Design freeze and manufacturability milestone imminent; scalable manufacturing capacity targeted at 130,000 units annually by 2029.

• Pre-CE study filing expected in Q2 2025, with pivotal human study to start late 2025, CE mark targeted in 2026, and European human market launch in 2027.

• Veterinary market launch planned for Q4 2025, with full European rollout in 2026.

• Revenue target of $200 million+ annually by 2030 from 75,000 patients, with EBITDA margin of 35%.

• Upcoming warrant exercise in June 2025 is a key funding milestone, expected to extend runway into 2026.